Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127 for drug discovery and mechanism of action (MOA) research

Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Efineptakin alfa A long-acting immunoglobulin (Ig) fusion protein composed of a recombinant form of the endogenous human protein interleukin-7 (rhIL-7) and fused to a hybrid Fc (hyFc) region of a human antibody, with hematopoietic and immunopotentiating activities. Upon administration of efineptakin alfa, IL-7 stimulates the proliferation, differentiation, trafficking and survival of a variety of T-cell subsets, including naive, central memory (CM), effector memory (EM), terminally differentiated effector memory (TEMRA) and natural killer (NK) T cells, and enhances T-cell-mediated anti-tumor immune responses.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-816-1mg	1mg	3090
GMP-Bios-INN-816-10mg	10mg	Inquiry
GMP-Bios-INN-816-100mg	100mg	Inquiry
GMP-Bios-INN-816-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Efineptakin Alfa Biosimilar, Fusion Protein targeting IL7R fused with human IGHG4 Fc (Fragment constant): Recombinant therapeutic protein targeting CD127/CDW127
INN Name	Efineptakin Alfa
Target	IL7R
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [IL7 (interleukin 7, IL- 7)]1 - IGHG4 Fc (Fragment constant)
VD LC	Fusion - [IL7 (interleukin 7, IL- 7)]1 - IGHG4 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Genexine (Seongnam South Korea)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0